108.26
前日終値:
$107.01
開ける:
$108.16
24時間の取引高:
826.42K
Relative Volume:
0.64
時価総額:
$6.67B
収益:
$3.99B
当期純損益:
$463.16M
株価収益率:
15.25
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+0.41%
1か月 パフォーマンス:
-7.00%
6か月 パフォーマンス:
-10.96%
1年 パフォーマンス:
+3.85%
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
名前
Jazz Pharmaceuticals Plc
セクター
電話
353-1-634-7800
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
JAZZ
Jazz Pharmaceuticals Plc
|
108.26 | 6.64B | 3.99B | 463.16M | 1.10B | 7.10 |
![]()
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-07 | アップグレード | UBS | Neutral → Buy |
2025-02-26 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2025-02-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2024-12-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-06-05 | 開始されました | Goldman | Buy |
2024-01-03 | 開始されました | Robert W. Baird | Outperform |
2023-11-27 | ダウングレード | UBS | Buy → Neutral |
2023-09-29 | 開始されました | Raymond James | Mkt Perform |
2023-06-12 | 再開されました | Wells Fargo | Equal Weight |
2022-12-09 | アップグレード | Goldman | Neutral → Buy |
2022-06-14 | 開始されました | UBS | Buy |
2022-04-06 | ダウングレード | Goldman | Buy → Neutral |
2021-11-19 | 再開されました | Goldman | Buy |
2021-10-07 | 再開されました | Jefferies | Buy |
2021-10-05 | 開始されました | Citigroup | Buy |
2021-09-23 | 開始されました | Needham | Buy |
2021-05-19 | 再開されました | JP Morgan | Overweight |
2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
2021-02-05 | 繰り返されました | H.C. Wainwright | Buy |
2021-02-03 | アップグレード | Piper Sandler | Neutral → Overweight |
2021-01-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-12-16 | 開始されました | UBS | Buy |
2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-09 | 繰り返されました | H.C. Wainwright | Buy |
2020-09-14 | ダウングレード | Goldman | Neutral → Sell |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-07-28 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-07-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-04-06 | 開始されました | Jefferies | Buy |
2020-03-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
2020-01-08 | 開始されました | Goldman | Neutral |
2019-08-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
2019-06-11 | 開始されました | Barclays | Overweight |
2019-03-20 | 開始されました | SunTrust | Buy |
2018-12-14 | 開始されました | Wolfe Research | Peer Perform |
2018-11-08 | 繰り返されました | B. Riley FBR | Buy |
2018-08-08 | 繰り返されました | Stifel | Buy |
2018-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2018-03-23 | 繰り返されました | H.C. Wainwright | Neutral |
2018-03-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
すべてを表示
Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG - Defense World
Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market: Drug Pipeline, - openPR.com
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - Yahoo Finance
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - Citizen Tribune
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Leadership to Present Strategic Updates at Two Major Healthcare Conferences in June - Stock Titan
Psychedelic Drugs Market Opportunities in the United States - openPR.com
Jazz Pharmaceuticals: One Step Forward, One Back (NASDAQ:JAZZ) - Seeking Alpha
Transcript : Jazz Pharmaceuticals plc Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Cut by Cubist Systematic Strategies LLC - Defense World
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook - Yahoo Finance
Mercer Global Advisors Inc. ADV Has $202,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz outlines $4.15B-$4.4B revenue target for 2025 amid growth in neuroscience portfolio and new oncology approvals - MSN
Weekly Investment Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ) - Defense World
July 18th Options Now Available For Jazz Pharmaceuticals - Nasdaq
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to “Hold” at StockNews.com - Defense World
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance - ADVFN
Jazz Pharmaceuticals at Bank of America 2025: Strategic Growth Amid Challenges - Investing.com Nigeria
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance
Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Royal Bank of Canada Has Lowered Expectations for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey
Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN
After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail
Jazz Earnings: Strong Demand for Epidiolex and Xywav Drive Growth; Shares Very Undervalued - Morningstar
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Down After Earnings Miss - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus
Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus
RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target - GuruFocus
Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus
RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanl - GuruFocus
Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Plc (JAZZ) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):